Alumis director James Tananbaum acquires $202,300 in stock

Published 07/05/2025, 03:00
Alumis director James Tananbaum acquires $202,300 in stock

James B. Tananbaum, a director at Alumis Inc. (NASDAQ:ALMS), has made significant acquisitions of the company’s common stock, according to a recent SEC filing. The purchases come as the stock trades near $4.35, down about 63% over the past six months, according to InvestingPro data. On May 2, Tananbaum purchased 25,000 shares at a price of $4.62 each, followed by an additional acquisition of 20,000 shares on May 6 at $4.34 per share. These transactions bring the total value of his purchases to approximately $202,300. The insider buying occurs as analysts maintain a strong buy consensus with price targets ranging from $14 to $29, suggesting significant upside potential. Following these acquisitions, Tananbaum’s indirect ownership, through various funds and entities, now includes a substantial number of shares in Alumis, which maintains a strong liquidity position with its cash holdings exceeding debt levels. Get more detailed insights and 8 additional key metrics with InvestingPro.

In other recent news, Alumis Inc. has announced a revised merger agreement with Acelyrin, which adjusts the share exchange ratio to increase Acelyrin stockholders’ ownership in the combined company to approximately 48%, while Alumis stockholders will own about 52%. The merger, anticipated to close in the second quarter of 2025, aims to create a leading biopharmaceutical company, with both boards unanimously recommending the transaction. Additionally, Alumis entered a strategic partnership with Kaken Pharmaceutical (TADAWUL:2070) for the development of ESK-001 in Japan, which includes $40 million in upfront and co-development payments and potential milestone payments up to $140 million. This collaboration is expected to leverage Kaken’s dermatology expertise to advance ESK-001’s market presence in Japan. H.C. Wainwright analysts recently adjusted their price target for Alumis to $14 from $15, maintaining a Buy rating, following the merger amendment. The analysts emphasized the strategic value of the merger in enhancing shareholder value amid challenging economic conditions. Furthermore, the partnership with Kaken could significantly bolster Alumis’s financial outlook, as it aligns with Kaken’s focus on novel dermatology treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.